Supplementary Table. Effectiveness of 2023–2024 Monovalent COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection Compared to Receipt of Bivalent Vaccination or Receipt of No Vaccination or Original Monovalent Vaccination Only, by Age Group and Interval Since Last Dose — Increasing Community Access to Testing Program, United States, September 2023–January 2024

Details

• Alternative Title:
  Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributableto Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024: Supplementary Table. Effectiveness of 2023–2024 Monovalent COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection Compared to Receipt of Bivalent Vaccination or Receipt of No Vaccination or Original Monovalent Vaccination Only, by Age Group and Interval Since Last Dose — Increasing Community Access to Testing Program, United States, September 2023–January 2024
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 4
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  73
• Issue:
  4
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:0e3ad83d98de1d2fcfa80f32936df4982f6b7da2fb0cde2bf5f18885ea755b02e133d0ec5ada0a94b5c368df6a031119fbecfef20fb66a945be8a5ab82dfc5e8
• Download URL:
  https://stacks.cdc.gov/view/cdc/145937/cdc_145937_DS1.pdf
• File Type:
  [PDF - 138.40 KB ]